SGLT2 inhibitors are a new treatment option for type 2 diabetes mellitus and exhibit their effects by inhibiting the reabsorption of glucose in the proximal renal tubules and increasing urinary glucose excretion [7]. This evidence concerns the gene SLC5A2 and diabetes mellitus.